CytRx ProTox
Executive Summary
Has been designated an orphan drug for initial therapy of toxoplasmosis in patients with AIDS, CytRx announced March 28. Toxoplasmosis is an opportunistic infection afflicting about 4% of AIDS patients. ProTox is in preclinicals, and the company said it hopes to file an IND "within the next six months.